Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages

Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

(2012) J. M. Gozgit et al.   MOLECULAR CANCER THERAPEUTICS

Suppression of Epidermal Growth Factor Receptor (EGFR) Expression by Small Hairpin RNA Inhibits the Growth of Human Nonsmall Cell Lung Cancers Bearing Wild-type and Mutant EGFR

(2011) Shuang Zhang et al.   CANCER INVESTIGATION

A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells

(2011) Hong Qiu et al.   CANCER LETTERS

E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models

(2011) Ezia Bello et al.   CANCER RESEARCH

Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

(2011) J.-W. Park et al.   CLINICAL CANCER RESEARCH

Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells

(2011) M. E. Marshall et al.   CLINICAL CANCER RESEARCH

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

(2011) K. B. Kim et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

(2011) K. Yamada et al.   CLINICAL CANCER RESEARCH

Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas

(2011) Shivaani Kummar et al.   EUROPEAN JOURNAL OF CANCER

Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer

(2011) Elizabeth Buck et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

(2011) Jonathan A. Ledermann et al.   JOURNAL OF CLINICAL ONCOLOGY

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Fibroblast Growth Factor Receptors as Therapeutic Targets in Human Melanoma: Synergism with BRAF Inhibition

(2011) Thomas Metzner et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2

(2011) Ning Xu et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

(2011) Vito Guagnano et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models

(2011) G. Zhao et al.   MOLECULAR CANCER THERAPEUTICS

AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo

(2011) Hua Xie et al.   PLoS One

Expression of Keratinocyte Growth Factor and Its Receptor in Rat Tracheal Cartilage: Possible Involvement in Wound Healing of the Damaged Cartilage

(2010) Takafumi Abo et al.   ACTA HISTOCHEMICA ET CYTOCHEMICA

Reduced Expression of Fibroblast Growth Factor Receptor 2IIIb in Hepatocellular Carcinoma Induces a More Aggressive Growth

(2010) Thomas Amann et al.   AMERICAN JOURNAL OF PATHOLOGY

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo

(2010) F R Lamont et al.   BRITISH JOURNAL OF CANCER

Inhibitory Effect of Small Interfering RNA Targeting Insulin-Like Growth Factor-I Receptor in Ovarian Cancer OVCAR3 Cells

(2010) Yuan An et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

(2010) Fumihiko Kanai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling

(2010) A. Bai et al.   CANCER RESEARCH

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)

(2010) Axel Le Cesne et al.   EUROPEAN JOURNAL OF CANCER

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic Activity of a Neutralizing Human Single-Chain Antibody Fragment against Fibroblast Growth Factor Receptor 1

(2010) R. Ronca et al.   MOLECULAR CANCER THERAPEUTICS

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

(2010) F. M. Iwamoto et al.   NEURO-ONCOLOGY

A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models

(2010) Yanlan Yu et al.   PLoS One

Effect of tumour-cell-derived or recombinant keratinocyte growth factor (KGF) on proliferation and radioresponse of human epithelial tumour cells (HNSCC) and normal keratinocytes in vitro

(2010) Andrea Hille et al.   RADIATION AND ENVIRONMENTAL BIOPHYSICS

The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events

(2010) Claude C. Warzecha et al.   RNA Biology

Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes

(2009) Xia Zhang et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

(2009) Jing Qing et al.   JOURNAL OF CLINICAL INVESTIGATION

The synthetic inhibitor of Fibroblast Growth Factor Receptor PD166866 controls negatively the growth of tumor cells in culture

(2009) Gianfranco Risuleo et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

1-tert-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a Selective Tyrosine Kinase Inhibitor of Fibroblast Growth Factor Receptor-3 (FGFR3), Inhibits Cell Proliferation of Bladder Cancer Carrying the FGFR3 Gene Mutation along with Up-Regulation of p27/Kip1 and G1/G0 Arrest

(2009) M. Miyake et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma

(2009) Michael G. Gartside et al.   MOLECULAR CANCER RESEARCH

ESRP1 and ESRP2 Are Epithelial Cell-Type-Specific Regulators of FGFR2 Splicing

(2009) Claude C. Warzecha et al.   MOLECULAR CELL

The FGF family: biology, pathophysiology and therapy

(2009) Andrew Beenken et al.   NATURE REVIEWS DRUG DISCOVERY

Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer

(2008) C. Behrens et al.   CLINICAL CANCER RESEARCH

Phase II Study of Palifermin and Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma

(2008) David M. Brizel et al.   JOURNAL OF CLINICAL ONCOLOGY

Modulation of the expression of the FGFR2-IIIb and FGFR2-IIIc molecules in dermatofibroma

(2008) Nevena Skroza et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Silencing of Keratinocyte Growth Factor Receptor Restores 5-Fluorouracil and Tamoxifen Efficacy on Responsive Cancer Cells

(2008) Sabrina Rotolo et al.   PLoS One

Drug-sensitive FGFR2 mutations in endometrial carcinoma

(2008) A. Dutt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions

(2008) Kumiko Maruyama-Takahashi et al.   PROSTATE

Aberrant expression of keratinocyte growth factor receptor in ovarian surface epithelial cells of endometrioma

(2007) Fuminori Taniguchi et al.   FERTILITY AND STERILITY